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Abstract 
Objectives. To describe trends in the epidemiology of gout and patterns of urate-lowering 
treatment (ULT) in the UK general population from 1997-2012. 
Methods. We used the Clinical Practice Research Datalink (CPRD) to estimate the prevalence 
and incidence of gout for each calendar year from 1997 to 2012. We also investigated the 
pattern of gout management for both prevalent and incident gout patients. 
Results. In 2012, the prevalence of gout was 2.49% (95% CI, 2.48%‒2.51%) and the incidence 
was 1.77 (95% CI, 1.73‒1.81) per 1,000 person-years. Prevalence and incidence both were 
significantly higher in 2012 than in 1997, with a 63.9% increase in prevalence and 29.6% 
increase in incidence over this period. Regions with highest prevalence and incidence were 
the North East and Wales. Among prevalent gout patients in 2012, only 48.48% (95% CI, 
48.08%‒48.89%) were being consulted specifically for gout or treated by ULT and of these 
37.63% (95% CI, 37.28%‒38.99%) received ULT. In addition, only 18.6% (95% CI, 17.6%‒19.6%) 
of incident gout patients received ULT within 6 months and 27.3% (95% CI, 26.1%‒28.5%) 
within 12 months of diagnosis. The management of prevalent and incident gout patients 
remained essentially the same during the study period, although the percentage of adherent 
patients improved from 28.28% (95% CI, 27.33%‒29.26%) in 1997 to 39.66% (95% CI, 39.11%‒
40.22%) in 2012. 
Conclusions. In recent years both the prevalence and incidence of gout have increased 
significantly in the UK. Suboptimal use of ULT has not changed between 1997 and 2012. 
Patient adherence has improved during the study period, but it remains poor.   
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Introduction 
Gout is the most common inflammatory arthritis with a diverse spectrum of clinical 
manifestations. In addition to recurrent acute arthritis, subcutaneous tophi and chronic 
painful arthritis,[1] it also has an impact on morbidity[2-4] and premature mortality.[5-7] Gout 
results from the deposition of monosodium urate (MSU) crystal in peripheral joints and soft 
issues due to persistent elevation of uric acid levels above the saturation point for crystal 
deposition. Effective urate-lowering treatment (ULT) that maintains uric acid below this critical 
level will prevent further MSU crystal formation and dissolve away existing crystals,[8] making 
gout the only chronic arthritis that can be ‘cured’. However, studies show that only a minority 
of gout patients receive effective treatment, the majority continuing to experience recurrent 
acute attacks, further joint damage and other complications.[9-12]  
In the United Kingdom, several studies have estimated the prevalence of gout since the 
1970’s.[13-20] Two of these both report a prevalence of 1.4% onward from 1999[18] to 
2005[19] suggesting a plateau of prevalence, whereas three studies using different 
population-based databases have reported a rise in the incidence of gout in the past 
decade.[18, 20, 21]  In addition, only approximately a quarter of gout patients in the UK 
receive ULT within one year from diagnosis,[21] which should contribute substantially to the 
elevated prevalence.  
Currently, UK data from the current millennium exploring gout incidence and prevalence, 
assessed at multiple time points in the same population, are sparse. Therefore, we undertook 
this study to examine the prevalence and incidence of gout and patterns of gout management 
using the Clinical Practice Research Datalink (CPRD) from 1997-2012. 
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 Methods 
The study was approved by the Trent Multi-centre Research Ethics Committee (reference 
number: 05/MRE04/87) and the Independent Scientific Advisory Committee (11-021R).   
Source of data  
The Clinical Practice Research Datalink (CPRD) is one of the largest databases of longitudinal 
medical records from primary care in the world. Established in 1987 and named the General 
Practice Research Database (GPRD) until April 2012, the CPRD has collected anonymised 
clinical records from around 12 million individuals, representing 8% of the UK population, with 
demonstrated reliable research standard data. A recent systematic review supported a high 
validity of recorded diagnoses in CPRD, with a median proportion of cases with a confirmed 
diagnosis of 89% for 183 different conditions.[22] 
Study population  
Our study comprised all participants who contributed data to the CPRD between 1st January 
1997 and 31th December 2012. The denominator for prevalence estimation (eligible 
population) for each calendar year included all individuals registered on 1st July of each 
calendar year with the general practices which were up-to-standard for CPRD research.  For 
incidence of gout we constructed at-risk cohorts for each calendar year which comprised all 
individuals registered with up-to-standard practices during the year specified who had no 
history of gout diagnosis before the latest of current registration date plus 365 days or 1st Jan 
of the calendar year specified. Person-years of follow-up were then calculated from the latest 
of 1st Jan or the date of registration plus 365 days to the earliest date of transfer-out, incident 
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gout diagnosis, death or 31st December of the specified year.  
Case definition of gout 
Prevalent cases of gout were defined as participants who had gout on 1st July of each calendar 
year, whereas incident cases of gout were those who had no gout prior to the latest of current 
registration date plus 365 days or 1st January of each calendar year but developed gout during 
the year were defined as incident cases of gout.  To be eligible as an incident case, participants 
had to have at least one-year registration prior to the first date of gout diagnosis.[21] Gout 
was defined as according to READ coding. Since some READ codes apparently indicate 
prevalent gout (such as history of gout), we only used 18 codes for incident gout identification 
but there were 39 codes for prevalent gout identification (see supplementary table 1). The 
case definition has been validated in a previous study.[23]  Meier et al reviewed medical 
records and laboratory results of 10 confirmed (with recorded diagnosis, elevated serum urate 
and drug treatment) and 28 probable (with recorded diagnoses and drug treatment) gout 
patients and ascertained 10 out of 10 confirmed cases and 24 out of probable cases to be true 
gout patients (overall positive predictive value 90%).  
Estimation of prevalence and incidence 
Prevalence was calculated using the number of people diagnosed with gout at any time before 
the mid-point of a calendar year as the numerator and the number of all individuals 
contributing CPRD data at the same time point as the denominator. Incidence was calculated 
using the number of incident gout cases during a calendar year as the numerator and the total 
person-years occurring during the same year as the denominator.  
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Prevalence and incidence were calculated for 13 regions in the UK: North East, North West, 
Yorkshire and the Humber, East Midlands, West Midlands, East of England, South West, South 
Central, London, South East Coast, Northern Ireland, Scotland, and Wales. To remove the 
effect of different age and gender structures in these regions, we standardised prevalence and 
incidence with the overall population structure using 2012 as the reference.  We used 
choropleth maps to represent geographic variations of gout in the UK.   
Pattern of treatment 
We studied the proportion of prevalent gout patients who were being consulted specifically 
for gout or being treated by ULT (allopurinol, febuxostat, benzbromarone, probenecid or 
sulfinpyrazone) in each calendar year during the period 1997-2012. We also estimated the 
proportion of incident patients who were treated by ULT within 6 months and 12 months of 
diagnosis.  
Adherence to ULT 
Adherence of ULT among prevalent gout patients was measured using proportion of days 
covered (PDC) to represent the degree of prescription-filling in a given interval specified. PDC 
was calculated as the proportion of days on which a patient had available prescriptions for 
ULT in each interval, which was defined as the period from the latest of registration date or 1st 
Jan to the earliest of transfer-out, death date or 31 Dec of the calendar year specified. For 
overlapping prescriptions, the later prescription was assumed to start from the end of the 
prior prescription; this was to avoid double counting of days covered. We then divided the 
gout patients into 4 groups according to status of being treated and adherence at each 
calendar year: not treated, non-adherent (those with a PDC less than 20%), partially adherent 
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(those with a PDC of 20% to 79%) and adherent (those with a PDC of at least 80%). We 
assessed the management of incident gout patients by the percentage of incident gout 
patients treated with ULT at 6 months and one year after diagnosis.  
Trends of prevalence, incidence and management of gout  
To determine the trends of prevalence, incidence and management of gout, we calculated 
age-, sex- and length of data contribution-standardised prevalence, incidence of gout and 
pattern of ULT in each calendar year from 1997 to 2012 with the population structure in year 
2012 as reference. The length of data contribution of each patient was defined as the period 
from the current date of registration to 1st July of each calendar year for prevalence, or to 1st 
Jan of the calendar year specified for incidence. The reasons to include length of data 
contribution to standardise prevalence, incidence and PDC were (1) prevalence, incidence and 
PDC estimation were subject to length of data contribution with a tendency toward higher 
prevalence and incidence (supplementary figure 1) and (2) the distribution of length of data 
contribution was different in calendar years studied, with longer length of data contribution 
in more recent years (supplementary figure 2).  
Statistical analysis 
The 95% confidence intervals (CIs) for prevalence and incidence were derived on the basis of 
the assumption of a Poisson distribution of the observed prevalent cases. We used the 
Joinpoint Regression Program (version 4.0.4) to estimate trends of prevalence and incidence 
of gout. The program uses Bayesian Information Criterion to generate different numbers of 
‘join points’ in time when the trend of prevalence and incidence of gout change significantly 
and to determine the best-fit data series.[24] Initially models contained zero joinpoints (i.e. a 
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straight line fitted to the data) with joinpoints added whenever a change in trend over time is 
statistically significant, with the user specifying the maximum number of allowable joinpoints. 
Using a Bayesian information criterion approach, we selected maximum of three joinpoints. 
Annual percentage changes (APC) for each segment and average annual percentage changes 
(AAPC) for the entire study period of prevalence and incidence were calculated. The 
significance level was set at 0.05. All statistical analyses were performed by using SAS 
statistical software, version 9.3.  
Role of the sponsors 
The sponsor of the study, University of Nottingham and Chang Gung Memorial Hospital, had 
no role in study design, collection, analysis and interpretation of the data and the preparation, 
review or approval of the paper.  
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Results 
Prevalence and incidence in 2012 
Of 4,634,974 eligible individuals in 2012, 115,608 prevalent cases of gout were identified, 
giving a prevalence of 2.49% (95% CI, 2.48%‒2.51%). Men had a significantly higher 
prevalence of gout (3.97%; 95% CI, 3.96%‒4.00%) than women (1.05%; 95% CI, 1.04%‒1.06%). 
This gender difference was observed in all ages with a male to female ratio of 1.5 in individuals 
younger than 20 years, peaking at 11.2 in those aged 35-39 years bands and then decreasing 
to 2.5 for those older than 90 years. Gout was rare in people younger than 20 years (5.11 cases 
per 100,000 individuals) and it increased with age thereafter.  In both men and women, the 
prevalence plateaued after the age of 80 years (figure 1a). In the adult population aged 20 
years of more, the prevalence of gout (95% CI) was 3.22% (3.20%‒3.23%) in overall population, 
5.17% (5.14%‒5.20%) in men and 1.34% (1.33%‒1.36%) in women.  
There were a total of 4,159,043 person-years of follow-up in this year during which 7,343 
incident cases of gout were identified (overall incidence 1.77 [95% CI, 1.73‒1.81] per 1000 
person-years). Men had a higher incidence of gout (2.58 [95% CI, 2.51‒2.65] per 1000 person-
year) than women (0.99 [95% CI, 0.95‒1.04]) per 1000 person year). As shown in figure 1b, 
incidence of gout was greatest in people aged 80-84 years in both men and women. The male 
to female ratio widened from the lowest in individuals younger than 20 years (1.2) to the a 
peak of 15.4 in those aged 30-34 years and thereafter the difference narrowed down. In adult 
population, the incidence of gout (95% CI) was 2.26 (2.21‒2.31) per 1,000 person-years in the 
adult population, 3.50 (3.26‒3.44) per 1,000 person-years in men and 1.25 (1.20‒1.31) per 
1,000 person-years in women. 
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Prevalence and incidence of gout between 1997 and 2012 
Table 1 shows the temporal trends in prevalence and incidence of gout from 1997 to 2012. In 
general, both crude and standardised estimates increased over time during this period. The 
standardised estimates were slightly higher than the crude ones, accounting for the fact that 
the average length of data contribution was higher in 2012 than 1997.  
The standardised prevalence of gout increased 63.9% over the study period. On average, the 
standardised prevalence increased 4.2% (95% CI, 3.9%‒4.5%) per year, suggesting the 
prevalence of gout in UK was increasing over the study period. Furthermore, there were two 
joinpoints at 2000 and 2008 with respective APCs of 1.3 (0.5‒2.1), 4.6 (4.3‒4.9) and 3.3 (2.8‒
3.8) for segment 1997‒2000, 2000‒2008 and 2008‒2012 respectively. As Figure 2a shows, the 
temporal trend of prevalence in men and women was not parallel (p <0.001). On average, 
prevalence in women increased 4.6% (95% CI, 4.3%‒5.0%) and was slightly higher than in men 
(4.1% [95% CI, 3.7%‒4.4%]). However, the male-to-female ratio was only slightly narrowed 
from 4.8 fold in 1997 to 4.3 fold in 2012. 
The standardised incidence also increased significantly (29.6%) during the study. On average, 
the incidence of gout increased 1.5% (95% CI, 1.1%‒1.9%) per year and there was only one 
join point (2003). The annual change of incidence increased 3.8% (95% CI, 2.7%‒4.9%) per 
year during the period between 1997 and 2003 but the incidence reached a plateau 
afterwards, with an annual change of 0.2 (95% CI, -0.4 to 0.9; p = 0.45). Figure 2b shows a very 
similar trend of gout incidence in men and women (p = 0.171), albeit a slightly higher average 
annual change in women (2.0%, 95% CI, 1.3%‒2.7%) than in men (1.5%, 95% CI, 0.9‒2.0%). 
The male to female ratio in incidence slightly reduced from 3.4 in 1997 to 3.0 in 2012.  
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Geographic variation in 2012 
Both prevalence and incidence of gout were not uniform throughout the UK. As shown in 
Figure 3, the standardised prevalence (95% CI) of gout was highest in the North East (3.11% 
[3.00%‒3.23%]) and Wales (2.98% [2.93‒3.02]). Regions with the lowest prevalence of gout 
were Scotland (2.02% [1.98%‒2.06%]) and Northern Ireland (2.15% [2.07‒2.22]). The East of 
England and Northern Ireland were the regions with the lowest standardised incidence (95% 
CI) of gout (1.50 [1.37‒1.65], 1.57 [1.45‒1.69] per 1000 patient-years respectively), while 
Wales and the North East had the highest incidence (2.28 [95% CI, 2.13‒2.43] and 2.17 [95% 
CI, 1.85‒2.54] per 1,000 patient-years respectively).  
Management of gout between 1997 and 2012 
Among prevalent gout patients in 2012, approximately half were being consulted specifically 
for gout or being treated by ULT (48.48%; 95% CI, 48.08%‒48.89%) and only one-third were 
being treated with ULT (37.63%, 95% CI, 37.28%‒38.99%). As shown in Figure 4a, the 
percentage of patients being consulted for gout or treated by ULT remained poor and almost 
constant during the study period, with a APC (95% CI) of -0.3% (-0.4% to -0.2%). Similarly, the 
percentage of patients being treated by ULT has not changed, with an APC of -0.1% (-0.2% to 
0.1%).  
In 2012, only 18.6% (95% CI, 17.6%‒19.6%) of incident gout patients received ULT within 6 
months and approximately one in four were treated within 12 months of diagnosis (27.3%; 
95% CI, 26.1%‒28.5%). As Figure 4b shows, the percentage of patients receiving ULT within 6 
and 12 months changed only marginally during the study period with APCs (95% CI) of -1.0% 
(-2.1 to 0.2; p = 0.100) and -0.8 (-1.6 to 0.1; p = 0.07), suggesting that the management of 
incident gout patients has remained essentially the same over the past 16 years. 
Adherence to urate-lowering treatment 
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Among ULT-treated patients in 2012 (n = 49395), 39.66% (95% CI, 39.11%‒40.22%) were 
adherent to treatment. Partially adherent and non-adherent patients comprised 42.84% (95% 
CI, 42.27%‒43.42%) and 17.50 (95% CI, 17.13%‒17.87%), respectively. In contrast to the 
percentage of patients receiving ULT, patient adherence to ULT improved in the past 16 years 
(figure 5). Overall, the percentage of adherent patients improved from 28.28% (95% CI, 
27.33%‒29.26%) in 1997 to 39.66% (95% CI, 39.11%‒40.22%) in 2012. The average APC was 
2.0 (95% CI, 1.5‒2.5). Joinpoints were attributed to 2002 and 2008, with APCs (95% CIs) of 4.5 
(2.6‒6.4) for 1997‒2002, 2.2 (1.0‒3.4) for 2002‒2008 and 0.0 (-1.3 to 1.4) for 2008‒2012. In 
contrast, the percentage of partially adherent and non-adherent patients reduced 13.0% and 
22.0% respectively. 
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Discussion 
This study demonstrates that the burden of gout in the UK is higher than previously thought, 
with approximately one in 40 adults being affected. Furthermore the prevalence of gout has 
continued to increase from 1997 to 2012 despite a stabilised incidence after 2005. Gout is not 
distributed uniformly within the UK, the highest prevalence and incidence of gout being in the 
North East and Wales. Unfortunately, despite this rising prevalence and the publication of 
European[25] and UK[26] guidelines in 2006 and 2007 respectively, the management of gout 
appears to be more than suboptimal with only one in three prevalent patients receiving ULT 
and only one in four newly diagnosed patients received ULT within one year of diagnosis. 
Although patient adherence to ULT has improved in the past decade this still remains poor.   
Early studies showed an increase in gout prevalence in the UK up until 1999, when a 
nationwide study by Mikuls et al. using the GPRD reported an overall prevalence of 1.39%.[18] 
Using the IMD analyser in the period  2000‒2005, Annemans et al. reported an identical 
prevalence of 1.4% suggesting that gout prevalence may have reached a plateau.[19] In 
contrast, our prevalence estimates were slightly higher during the period 1999‒2005 and 
continued to increase throughout the study period. We consider this disparity to primarily 
result from different degrees of identification of clinically silent patients, whose identification 
depends on a period of data contribution that is long enough to include a prior gout event. 
However, it is difficult to determine how many years of observation are sufficient to exclude 
this bias since data on length of asymptomatic inter-critical gout period are sparse. Only one 
case series in 1961 reported that the length of inter-critical periods was less than 1 year in 
62%, 1-5 years in 27%, 6-10 years in 4% and over 10 years in 7% of 614 patients.[27] Therefore, 
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we did not set a minimal length of data contribution but instead utilised direct standardisation 
considering age, sex and length of data contribution to circumvent the incomplete 
identification of inter-critical gout patients. Therefore, studies that have not examined prior 
data contribution will have underestimated the prevalence of gout in the UK.  When this bias 
is avoided it is apparent that the standardised prevalence of gout has risen since 1997. In 
addition, the prevalence of gout in the UK is higher than recent estimates in other European 
countries, specifically 1.4% in Germany [19] and 0.91% in Italy.[28] 
Very few studies have addressed the incidence of gout. Using data from the UK Second and 
Third National Studies of Morbidity in General Practice in the UK, overall gout incidence was 
estimated to be 1.4 per 1000 person-years in 1981.[29] Incidence estimates based on the 
GPRD ranged from 1.19 to 1.80 per 1,000 person-years in the period 1990‒1999[18] and those 
based on the Royal College of General Practitioners Weekly Returns Service (WRS) ranged 
from 1.12 and 1.35 per 1,000 population between 1994 and 2007. Another study using the 
THIN database reported an incidence of 2.68 per 1,000 person-years in the adult population 
in the period 2000‒2007.[30] Our estimates of incidence in general fall within these previous 
reported ranges. However, we found that the incidence of gout has increased by more than 
one quarter during the study period. Although it reached a plateau after 2004, it has shown 
no signs of subsequent reduction, a finding echoed by our observations of an increasing 
prevalence. Therefore gout will remain a commonly encountered disorder and the prevalence 
may even continue to rise in the near future. 
In addition to temporal changes we also documented clear evidence for regional variations in 
gout. The patterns for prevalence and incidence were similar, with the North East and Wales 
having the highest estimates for both. Regional variation within the UK has been noted 
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previously in just two studies. In a survey in 1975 Currie et al. reported a higher prevalence of 
gout in England than in Wales[14] and in 2982 Gardner et al. reported a lower prevalence 
(3.9%) in adults over age 45 in Ipswich in Suffolk than in the two more northern towns of 
Wakefield (4.5%) and Preston (4.9%).[15] To the best of our knowledge, there are no previous 
reports of geographical variation in incidence of gout in the UK. The reasons for current 
geographic variation in gout most likely relate to differences in socioeconomic status, life-style 
and nutrition and although gout historically was considered a disease of affluence, the 
converse may now be true. The UK morbidity statistics from general practice (1970-71) 
reported that people with non-manual skilled occupations had the highest whereas 
professional occupations had the lowest standardised consulting ratio for gout (133 vs. 79)[31] 
and Gardner’s study found a lower prevalence of gout in the town with the most favourable 
socioeconomic status.[15] In addition, a recent New Zealand study also found that the least 
deprived people had the lowest risk of gout.[32]  However, further studies are needed to 
explore the reasons for current variation by socioeconomic group and region.  
Regardless of the increasing prevalence and incidence of gout in the UK, the management of 
the disease remains poor. We found that throughout 1997‒2012 only around one third of 
people with prevalent gout were prescribed ULT. The management for incident gout patients 
also remained unchanged with only a quarter to a third of patients being treated with ULT 
within one year of diagnosis. This shows no significant change in overall usage of ULT from 
Mikuls’ estimates of 25.3%-29.5% from 1990 to 1999[18]. Apart from under-prescribing of ULT, 
Mikuls et al identified inappropriate prescribing of ULT in one quarter to one half of those 
people in whom quality indicators could be assessed[33] and a more recent study also 
demonstrated suboptimal care in many aspects of gout management.[34] Collectively, these 
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results reflect widespread lack of knowledge of gout and poor alignment with current 
recommendations of best practice within the UK.[35-37] Although guidelines do not explicitly 
advise discussion of ULT with every gout patient around the time of diagnosis, the majority of 
patients will have recommended specific indications (e.g.further attacks,[27] renal 
impairment,[38] required chronic diuretic use,[38] nephrolithiasis,[39] peripheral joint 
damage or tophi[40]) at diagnosis or within 6-12 months. Furthermore, increasingly the trend 
is towards early treatment with ULT to prevent people developing further crystal deposition 
and complications such as subcutaneous tophi and joint damage.[37]  Best practice requires 
full patient information concerning gout and its treatment [25, 26, 37] and in one recent UK 
study, when patients received this 100% wished to receive ULT.[36, 37] Being that gout is the 
only chronic arthritis for which there is “curative” treatment, the use of ULT would seem a 
useful indicator of standard of care.[37]   
We also found that only approximately 40% of treated patients in 2012 adhered to ULT. This 
accords with a recent review of six studies which reported that only 18% to 44% of patients 
with gout adhere to ULT.[41] Such poor adherence to ULT has long been recognised, one 
review finding adherence in gout patients to be the worst of seven chronic diseases requiring 
chronic medication.[42] Nevertheless, we did find an encouraging signal of a 40% 
improvement in percentage of adherent patients from 1997 to 2012. Although previous 
studies largely blame patients for poor adherence,[41, 43] a recent study indicated that 
appropriate patient education can effectively maintain high adherence to ULT and achieve 
therapeutic target in nine out of ten gout patients.[44] Therefore, as with low rates of ULT 
prescription, it is likely that the fault lies more with the health practitioners than with the 
patients.[37] There are many recognised barriers to care of gout, both in patients and 
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practitioners, but practitioner education seems the first prerequisite to address these 
problems. 
There are several limitations to the study. Firstly, we based our case definition on diagnosis by 
the general practitioners, rather than according to American College of Rheumatology[45] or 
Rome[46] classification criteria or to the 'gold standard' of urate crystal identification and this 
may lead to misclassification bias. However, the validity of gout diagnosis in the CPRD has 
been investigated and found to be high.[23]  Secondly, we based our adherence estimation on 
PDC, which is generally believed to be more conservative than the more commonly used 
measure of medication possession ratio. We assumed patients took all prescribed pills since 
calculation of PDC relies on records of prescription refills, but this assumption may not hold 
true and may have led to an overestimation of adherence. 
In conclusion, both the prevalence and incidence of gout have risen in the past 16 years and 
are the highest reported within Europe. However, despite being the commonest inflammatory 
arthritis the suboptimal management of gout continues unchanged, with only a minority of 
patients receiving ULT and new patients not being treated in a timely fashion.  Although 
somewhat improved patient adherence to ULT remains poor.  It is apparent that educational 
initiatives to improve practitioner knowledge, interest and standard of care of the only 
“curable” form of inflammatory arthritis are urgently required.  
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